Skip to Main Content

Paper Details

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.
Leukemia
11
2020
ERBB2, HER2, leukemia
Antineoplastic Agents, Immunological, Biomarkers, Tumor, Cell Transformation, Neoplastic, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Female, Humans, Leukemia, Molecular Targeted Therapy, Mutation, Protein Kinase Inhibitors, Receptor, ErbB-2, Treatment Outcome
Author NameAffiliation
Sunil K JoshiKnight Cancer Institute, Oregon Health & Science University
Sunil K JoshiOregon Health & Science University
Sunil K JoshiOregon Health & Science University
Jamie M KeckKnight Cancer Institute, Oregon Health & Science University
Jamie M KeckCenter for Spatial Systems Biomedicine, Oregon Health & Science University
Christopher A EideKnight Cancer Institute, Oregon Health & Science University
Christopher A EideOregon Health & Science University
Daniel BottomlyKnight Cancer Institute, Oregon Health & Science University
Elie TraerKnight Cancer Institute, Oregon Health & Science University
Elie TraerOregon Health & Science University
Elie TraerOregon Health & Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University
Jeffrey W TynerOregon Health & Science University
Jeffrey W TynerOregon Health & Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health & Science University
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University
Cristina E TognonOregon Health & Science University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerOregon Health & Science University
Brian J DrukerOregon Health & Science University
  • 1 - 21

Datasets

Release 1.2